<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:media="http://search.yahoo.com/mrss/">
  <channel>
    <title>Cancer</title>
    <description>
      <![CDATA[]]>
    </description>
    <link>https://www.bioworld.com/rss</link>
    <language>en-us</language>
    <item>
      <title>Metis Techbio, Impact Tx cleared for Hong Kong IPOs</title>
      <description>
        <![CDATA[Metis Techbio Co. Ltd. is seeking a potential HK$2.11 billion (US$270 million) raise through a stock sale May 13, marking the largest biotech raise on the Hong Kong Stock Exchange this year to date. Hangzhou, China-based Metis is an AI-based nanoparticle drug formulation and delivery-focused company. Synthetic lethality-based cancer drugmaker Impact Therapeutics Inc., of Shanghai, plans to debut on the same day with a US$117 million IPO.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731048</guid>
      <pubDate>Tue, 12 May 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731048-metis-techbio-impact-tx-cleared-for-hong-kong-ipos</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Money/Businessman-and-IPO-virtual-screen.webp?t=1717791671" type="image/jpeg" medium="image" fileSize="332138">
        <media:title type="plain">Businessman and IPO virtual screen</media:title>
      </media:content>
    </item>
    <item>
      <title>Advancing the 'best of both' – BMS, Hengrui enter $15.2B deal</title>
      <description>
        <![CDATA[In a deal potentially worth up to $15.2 billion, Jiangsu Hengrui Pharmaceuticals Co. Ltd. is joining efforts with Bristol Myers Squibb Co. to advance 13 early development programs in the fields of oncology, hematology and immunology. Shanghai-based Hengrui will hold exclusive rights in mainland China, Hong Kong and Macau, while Princeton, N.J.-based BMS will hold exclusive rights in the rest of the world. The deal includes four oncology/hematology assets from Hengrui, four immunology assets from BMS, and five assets that the two companies will jointly discover and develop.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731047</guid>
      <pubDate>Tue, 12 May 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731047-advancing-the-best-of-both-bms-hengrui-enter-152b-deal</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Research-and-science/Drug-research-illustration2.webp?t=1642547340" type="image/png" medium="image" fileSize="473295">
        <media:title type="plain">Test tubes, dropper and capsules</media:title>
      </media:content>
    </item>
    <item>
      <title>Coming through on Veppanu with back-loaded Rigel deal</title>
      <description>
        <![CDATA[Rigel Pharmaceuticals Inc. CEO Raul Rodriguez said breast cancer therapy Veppanu (vepdegestrant) could become his firm’s “largest product with the current label,” and other opportunities with the drug are lined up behind, albeit “still a bit early.”]]>
      </description>
      <guid>http://www.bioworld.com/articles/731045</guid>
      <pubDate>Tue, 12 May 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731045-coming-through-on-veppanu-with-back-loaded-rigel-deal</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Money/Gold-dollar-sign-inside-gold-cog.webp?t=1637008509" type="image/png" medium="image" fileSize="305471">
        <media:title type="plain">Gold dollar sign inside gold cog</media:title>
      </media:content>
    </item>
    <item>
      <title>Zhongshan Institute for Drug Discovery synthesizes YAP1/TEAD interaction inhibitors</title>
      <description>
        <![CDATA[Zhongshan Institute for Drug Discovery has divulged new transcriptional coactivator YAP1/transcriptional enhancer factor (TEAD) interaction inhibitors potentially useful for the treatment of cancer, neurodegeneration, malaria, AIDS, gout, diabetes, renal failure and cardiovascular disorders, among others.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731027</guid>
      <pubDate>Tue, 12 May 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731027-zhongshan-institute-for-drug-discovery-synthesizes-yap1-tead-interaction-inhibitors</link>
    </item>
    <item>
      <title>Architect Therapeutics reports new CDK2 inhibitors</title>
      <description>
        <![CDATA[Architect Therapeutics Inc. has identified new spiro heterocyclic cyclin-dependent kinase 2 (CDK2) inhibitors potentially useful for the treatment of cancer, myeloproliferative, autoimmune disease, inflammatory disorder, viral infections and fibrosis.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731026</guid>
      <pubDate>Tue, 12 May 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731026-architect-therapeutics-reports-new-cdk2-inhibitors</link>
    </item>
    <item>
      <title>Tango Therapeutics patents new HBS1L degradation inducers</title>
      <description>
        <![CDATA[Tango Therapeutics Inc. has disclosed new HBS1-like protein (HBS1L; HBS1) degradation inducers potentially useful for the treatment of cancer.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731023</guid>
      <pubDate>Tue, 12 May 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731023-tango-therapeutics-patents-new-hbs1l-degradation-inducers</link>
    </item>
    <item>
      <title>HEC Pharma presents oral small-molecule PD-L1 inhibitor</title>
      <description>
        <![CDATA[HEC Pharma Co. Ltd. recently presented HEC-201625, a small-molecule PD-L1 inhibitor for cancer immunotherapy that blocks the PD-1/PD-L1 signaling pathway. HEC-201625 was tested in vitro and in vivo in MC38 syngeneic murine model, as well as in xenograft A375 and NCI-H358 models.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731017</guid>
      <pubDate>Tue, 12 May 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731017-hec-pharma-presents-oral-small-molecule-pd-l1-inhibitor</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/Cells-receptors-inhibitors.webp?t=1667926694" type="image/png" medium="image" fileSize="1347625">
        <media:title type="plain">Concept art for cells receptors, inhibitors</media:title>
      </media:content>
    </item>
    <item>
      <title>In vivo mRNA gene therapy platform reprograms cytotoxic T cells </title>
      <description>
        <![CDATA[A new mRNA and lipid nanoparticle (mRNA-LNP) platform could selectively reprogram in vivo cytotoxic effector T cells (Teff), the cells responsible for eliminating infected or tumor cells. To achieve this, scientists at the University of Pennsylvania conjugated LNPs with fractalkine, a molecule that binds to the CX3CR1 receptor, which is a marker of Teff cells. Using this strategy, the researchers delivered an mRNA encoding new proteins such as IL‑2 or human CD62 L‑selectin, opening the door to temporarily reprogramming these cells within the body, both in the blood and in lymphoid tissue, where they reside and become activated.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731155</guid>
      <pubDate>Mon, 11 May 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731155-in-vivo-mrna-gene-therapy-platform-reprograms-cytotoxic-t-cells</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Research-and-science/T-cell-gray-and-red-.webp?t=1778264740" type="image/jpeg" medium="image" fileSize="165631">
        <media:title type="plain">Gray and red T cell</media:title>
      </media:content>
    </item>
    <item>
      <title>Yantai Rongchang Pharmaceutical reports new KRAS mutant inhibitors</title>
      <description>
        <![CDATA[Yantai Rongchang Pharmaceutical Co. Ltd. has synthesized new GTPase KRAS mutant inhibitors potentially useful for the treatment of pancreatic cancer.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731009</guid>
      <pubDate>Mon, 11 May 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731009-yantai-rongchang-pharmaceutical-reports-new-kras-mutant-inhibitors</link>
    </item>
    <item>
      <title>Hefei Shengpu Pharmaceutical synthesizes new GTPase KRAS mutant inhibitors</title>
      <description>
        <![CDATA[Hefei Shengpu Pharmaceutical Technology Co. Ltd. has divulged new GTPase KRAS mutant inhibitors potentially useful for the treatment of cancer.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731005</guid>
      <pubDate>Mon, 11 May 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731005-hefei-shengpu-pharmaceutical-synthesizes-new-gtpase-kras-mutant-inhibitors</link>
    </item>
    <item>
      <title>Soley Therapeutics reports data on new CKAP2 modulator STX-6398</title>
      <description>
        <![CDATA[Cytoskeleton-associated protein 2 (CKAP2) is the most potent microtubule growth factor identified so far and is considered an undruggable protein, often associated with malignant progression in cancer by targeting the FAK-ERK2 signaling pathway. Using its proprietary platform, Soley Therapeutics Inc. has discovered a small molecule that modulates CKAP2 – STX-6398.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730999</guid>
      <pubDate>Mon, 11 May 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730999-soley-therapeutics-reports-data-on-new-ckap2-modulator-stx-6398</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/Doctor-chemistry-molecule-science-research.webp?t=1778511298" type="image/jpeg" medium="image" fileSize="481427">
        <media:title type="plain">Doctor hand touching virtual molecular structure</media:title>
      </media:content>
    </item>
    <item>
      <title>Singlomics’ DXP-106 shows robust results in preclinical setting</title>
      <description>
        <![CDATA[The interleukin-1 receptor accessory protein (IL1RAP) is expressed in cancer cells within the tumor microenvironment of several cancer types and plays a role in tumor development. DXP-106 is a humanized monoclonal antibody developed by Singlomics Biopharmaceuticals Co. Ltd. that binds to a unique epitope of IL1RAP domain 2 that competes with cytokines.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730998</guid>
      <pubDate>Mon, 11 May 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730998-singlomics-dxp-106-shows-robust-results-in-preclinical-setting</link>
    </item>
    <item>
      <title>Shanghai Ailux Biotechnology synthesizes FGFR2-targeting ADCs</title>
      <description>
        <![CDATA[Shanghai Ailux Biotechnology Co. Ltd. has patented new antibody-drug conjugates consisting of an antibody targeting fibroblast growth factor receptor 2 isoform 2 (FGFR2; FGFR2b) covalently linked to a cytotoxic drug intended for use in the treatment of cancer.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730963</guid>
      <pubDate>Fri, 08 May 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730963-shanghai-ailux-biotechnology-synthesizes-fgfr2-targeting-adcs</link>
    </item>
    <item>
      <title>Hangzhou Bio Sincerity Pharma-Tech identifies new exportin-1 receptor antagonists</title>
      <description>
        <![CDATA[Hangzhou Bio Sincerity Pharma-Tech Co. Ltd. has reported crylamide compounds acting as exportin-1 (CRM1; XPO1) receptor antagonists found to be useful for the treatment of cancer.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730962</guid>
      <pubDate>Fri, 08 May 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730962-hangzhou-bio-sincerity-pharma-tech-identifies-new-exportin-1-receptor-antagonists</link>
    </item>
    <item>
      <title>University of California discloses new PRKACA-targeting PROTACs</title>
      <description>
        <![CDATA[The University of California has identified proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase Von Hippel-Lindau disease tumor suppressor (VHL)-binding moiety coupled to cAMP-dependent protein kinase catalytic subunit α (PRKACA) targeting moiety through a linker.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730961</guid>
      <pubDate>Fri, 08 May 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730961-university-of-california-discloses-new-prkaca-targeting-protacs</link>
    </item>
    <item>
      <title>Treeline Biosciences patents new RAS inhibitors</title>
      <description>
        <![CDATA[Treeline Biosciences Inc. has disclosed macrocyclic compounds acting as RAS inhibitors that are potentially useful for the treatment of pancreatic cancer (ductal adenocarcinoma) and melanoma.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730960</guid>
      <pubDate>Fri, 08 May 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730960-treeline-biosciences-patents-new-ras-inhibitors</link>
    </item>
    <item>
      <title>Impact Therapeutics discovers new Wee1 inhibitors</title>
      <description>
        <![CDATA[Impact Therapeutics (Shanghai) Inc. has prepared and tested Wee1-like protein kinase (Wee1) inhibitors reported to be useful for the treatment of cancer.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730959</guid>
      <pubDate>Fri, 08 May 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730959-impact-therapeutics-discovers-new-wee1-inhibitors</link>
    </item>
    <item>
      <title>Takeda’s anti-CCR8 ADC shows potent antitumor activity</title>
      <description>
        <![CDATA[Researchers from Takeda Pharmaceutical Co. Ltd. detailed the preclinical characterization of TAK-188, a first-in-class anti-CCR8 antibody-drug conjugate (ADC) designed to selectively target CCR8+ Tregs, alleviating immunosuppression in the tumor microenvironment.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730954</guid>
      <pubDate>Fri, 08 May 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730954-takedas-anti-ccr8-adc-shows-potent-antitumor-activity</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Cancer/TME-tumor-microenvironment-3D.webp?t=1699370810" type="image/jpeg" medium="image" fileSize="457538">
        <media:title type="plain">3D Rendering of tumor microenvironment</media:title>
      </media:content>
    </item>
    <item>
      <title>BD-200 is strong dual-targeting ADC candidate for cancer</title>
      <description>
        <![CDATA[Biolojic Design Ltd. has reported preclinical data for its antibody-drug conjugate (ADC) BD-200, developed using an AI-guided antibody engineering platform named Multibody.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730953</guid>
      <pubDate>Fri, 08 May 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730953-bd-200-is-strong-dual-targeting-adc-candidate-for-cancer</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/Immune-antibody-drug-capsule.webp?t=1778251154" type="image/png" medium="image" fileSize="660418">
        <media:title type="plain">3D rendering of a drug capsule and flying antibodies</media:title>
      </media:content>
    </item>
    <item>
      <title>New assay for drug discovery against chemo-induced peripheral neuropathy</title>
      <description>
        <![CDATA[A group led by researchers at Boston Children’s Hospital established a scalable and reproducible model of paclitaxel-induced axon degeneration and neurotoxicity in human induced pluripotent stem cell (iPSC)-derived sensory neurons.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730951</guid>
      <pubDate>Fri, 08 May 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730951-new-assay-for-drug-discovery-against-chemo-induced-peripheral-neuropathy</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Neurology/Neurology-neuron-pathways.webp?t=1685635688" type="image/jpeg" medium="image" fileSize="225697">
        <media:title type="plain">Concept art for "unlocking the secrets of the mind"</media:title>
      </media:content>
    </item>
    <item>
      <title>FDA clears IND for Harbour Biomed’s HBM-7004</title>
      <description>
        <![CDATA[Harbour Biomed has gained IND clearance from the FDA for HBM-7004, enabling the initiation of a first-in-human phase I trial in subjects with advanced solid tumors. ]]>
      </description>
      <guid>http://www.bioworld.com/articles/730950</guid>
      <pubDate>Fri, 08 May 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730950-fda-clears-ind-for-harbour-biomeds-hbm-7004</link>
    </item>
    <item>
      <title>Seed financing at Parcelbio to advance mRNA medicines</title>
      <description>
        <![CDATA[Parcelbio has raised $13 million in seed financing to continue its development of a new class of potent and durable mRNA medicines. The financing will support development of Parcelbio’s proprietary APEXm (Amplified and Prolonged EXpression mRNA) platform and advance its pipeline, including its lead in vivo CAR T program for autoimmune disease.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730949</guid>
      <pubDate>Fri, 08 May 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730949-seed-financing-at-parcelbio-to-advance-mrna-medicines</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/Mrna-therapeutic-illustration.webp?t=1778251655" type="image/png" medium="image" fileSize="958605">
        <media:title type="plain">Illustration of messenger RNA</media:title>
      </media:content>
    </item>
    <item>
      <title>Arrivent’s MUC16/NaPi2b-targeted ADC gains IND clearance</title>
      <description>
        <![CDATA[Arrivent Biopharma Inc. has obtained IND clearance from the FDA for ARR-002 (AV-P138-ADC), an antibody-drug conjugate (ADC) with an initial focus in ovarian and endometrial cancers and broader therapeutic potential across solid tumors. A phase I trial is expected to open in the second half of the year.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730948</guid>
      <pubDate>Fri, 08 May 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730948-arrivents-muc16-napi2b-targeted-adc-gains-ind-clearance</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Cancer/Female-reproductive-system-and-cancer-cells.webp?t=1698266547" type="image/jpeg" medium="image" fileSize="414946">
        <media:title type="plain">Female reproductive system and cancer cells</media:title>
      </media:content>
    </item>
    <item>
      <title>Phase II Engene trouble: NMIBC detalimogene data throttle stock </title>
      <description>
        <![CDATA[Hopes piqued last November for detalimogene voraplasmid in bladder cancer took a hit from the latest word from the study, as did shares of Engene Therapeutics Inc. (NASDAQ:ENGN), which closed May 7 at $1.72, down 80.6%, or $7.13.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730968</guid>
      <pubDate>Thu, 07 May 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730968-phase-ii-engene-trouble-nmibc-detalimogene-data-throttle-stock</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Urology/Bladder-illustration.webp?t=1615559821" type="image/png" medium="image" fileSize="432209">
        <media:title type="plain">Bladder </media:title>
      </media:content>
    </item>
    <item>
      <title>Roche to acquire Pathai for up to $1.05B</title>
      <description>
        <![CDATA[Roche Holding AG has agreed to acquire Pathai Inc. for up to $1.05 billion in a bid to strengthen its position in digital pathology and enhance its biopharma services. The move builds on a partnership established between the two companies in 2021, and expanded in 2024, to include the development of AI-enabled companion diagnostic algorithms.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730966</guid>
      <pubDate>Thu, 07 May 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730966-roche-to-acquire-pathai-for-up-to-105b</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Misc/Roche-building.webp?t=1698088417" type="image/jpeg" medium="image" fileSize="310241">
        <media:title type="plain">Roche building</media:title>
        <media:description type="plain">Credit: F. Hoffmann-La Roche Ltd.</media:description>
      </media:content>
    </item>
    <item>
      <title>KRAS inhibitors disclosed in Sunrise Oncology patent</title>
      <description>
        <![CDATA[Sunrise Oncology (Hong Kong) Ltd. has synthesized new condensed macrocyclic compounds acting as GTPase KRAS inhibitors potentially useful for the treatment of cancer.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730944</guid>
      <pubDate>Thu, 07 May 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730944-kras-inhibitors-disclosed-in-sunrise-oncology-patent</link>
    </item>
    <item>
      <title>Insmed reports new cathepsin C inhibitors</title>
      <description>
        <![CDATA[Insmed Inc. has identified new cathepsin C (dipeptidyl peptidase I; DPP1) inhibitors potentially useful for the treatment of cancer, inflammatory bowel disease, bronchiectasis, asthma, cystic fibrosis, lupus nephritis, pulmonary hypertension and rheumatoid arthritis.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730942</guid>
      <pubDate>Thu, 07 May 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730942-insmed-reports-new-cathepsin-c-inhibitors</link>
    </item>
    <item>
      <title>HK Inno.N patents new MAP4K1 inhibitors</title>
      <description>
        <![CDATA[HK Inno.N Corp. has disclosed new 5-cyclopropylpicolinamide derivatives acting as mitogen-activated protein kinase kinase kinase kinase 1 (MAP4K1; HPK1; MEKKK1) inhibitors potentially useful for the treatment of cancer.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730941</guid>
      <pubDate>Thu, 07 May 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730941-hk-innon-patents-new-map4k1-inhibitors</link>
    </item>
    <item>
      <title>ZMS-2195 is a potent multi-RAS strategy for RAS-dependent tumors</title>
      <description>
        <![CDATA[Simcere Zaiming Pharmaceutical Co. Ltd. has detailed the discovery and preclinical characterization of ZMS-2195, a multiple-RAS inhibitor designed to prevent both mutant and wild-type forms of KRAS, NRAS and HRAS from binding to the RAS-binding domain (RBD) of RAF, which is required to activate downstream MAPK signaling.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730936</guid>
      <pubDate>Thu, 07 May 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730936-zms-2195-is-a-potent-multi-ras-strategy-for-ras-dependent-tumors</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Research-and-science/RAS-protein.webp?t=1681852766" type="image/png" medium="image" fileSize="402873">
        <media:title type="plain">RAS protein</media:title>
      </media:content>
    </item>
    <item>
      <title>Biosion’s BSI-737 exerts strong antitumor activity</title>
      <description>
        <![CDATA[Biosion Inc. recently presented preclinical data describing their B7H3/PD-L1 bispecific antibody-drug conjugate (ADC) BSI-737 for the treatment of cancer.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730935</guid>
      <pubDate>Thu, 07 May 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730935-biosions-bsi-737-exerts-strong-antitumor-activity</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Cancer/Cancer-cell-target-destroy.webp?t=1731081970" type="image/jpeg" medium="image" fileSize="520172">
        <media:title type="plain">Illustration of cancer cell in crosshairs being destroyed</media:title>
      </media:content>
    </item>
  </channel>
</rss>
